IceCure Medical gains after ProSense update, $5.5M placement
NEW YORK, June 18, 2026, 07:07 (EDT)
- IceCure ended trading Wednesday at $6.40, rising 200.47%. The stock was last seen at $7.27 before the bell at 6:59 a.m. EDT.
- The company set the price for a $5.5 million private placement at $3.00 a share, including warrants. It plans to use the money for working capital and general corporate purposes.
- IceCure reported its active U.S. ProSense install base for breast cancer cryoablation jumped 70% after getting FDA marketing approval, according to a separate update. Nasdaq is closed Friday for Juneteenth.
IceCure Medical shares looked headed for another choppy day Thursday, after the Israeli medical-device firm gave a U.S. commercial update and announced fresh financing. The stock, listed on Nasdaq, jumped 200.47% to $6.40 on Wednesday. Early pre-market data from Webull put it at $7.27 as of 6:59 a.m. EDT.
This pick-up matters for investors now as they look at early U.S. adoption of ProSense following FDA marketing clearance, all while fresh equity supply hangs over the shares. Cryoablation uses freezing to destroy tissue—offering a less invasive option than surgery in certain cases.
IceCure said Wednesday it’s selling 1,833,334 ordinary shares and Series D and Series E warrants to one institutional investor with a focus on healthcare. The total price is $3.00 per share with attached warrants. The deal is a private placement, not a public offering.
The company is targeting about $5.5 million in gross proceeds before fees, with the deal set to close on or around June 18, as long as typical closing conditions are met. Funds raised will go to working capital and general corporate needs. The warrants have a $3.00 exercise price; Series D warrants run for five years, Series E warrants for one year.
IceCure reported Wednesday its active U.S. install base for ProSense, aimed at breast cancer cryoablation, is up 70% since getting FDA clearance in October 2025. The company says the procedure has now been used in Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis, and other cities.
Chief Executive Eyal Shamir said the company is in the “early stages of a significant commercial opportunity” in U.S. breast cancer cryoablation. Shamir also said physician training and education matter, along with getting wider patient access. PR Newswire
IceCure said ProSense is cleared for local treatment of low-risk breast cancer with adjuvant endocrine therapy in women 70 and older, even those who can’t have surgery. Adjuvant endocrine therapy is a hormone-blocking treatment after a local procedure to lower the risk of the cancer coming back.
Commercial pressure, not just regulatory hurdles, is driving the test. Big med-tech players already have ablation devices out, like Boston Scientific’s ICEfx system for minimally invasive cryoablation, and Varian/Siemens Healthineers with their CryoCare Touch system. IceCure is making a push for market share, focusing on its breast-cancer indication and an office-based setup.
But the new financing could put a lid on the rally if traders eye dilution over the added cash. IceCure is also planning, pending shareholder signoff and Nasdaq OK, to lower the strike price for some March 2026 warrants to $3.00 from $16.50. That would put more shares on the table if exercised later. The company flagged risks in sales execution, funding, regulatory issues, intellectual property, and instability in Israel and the Middle East as factors that might impact results.
Nasdaq’s regular session opens at 9:30 a.m. EDT and ends at 4 p.m. EDT. The exchange will be closed Friday, June 19, for Juneteenth. Pre-market runs 4 a.m. to 9:30 a.m., with extended-hours trading often thinner and more volatile, Nasdaq says. NasdaqNEW YORK, June 18, 2026, 07:07 (EDT)
- IceCure ended Wednesday at $6.40, rallying 200.47%. The stock was last seen at $7.27 ahead of the bell at 6:59 a.m. EDT.
- The company lined up a $5.5 million private placement, selling shares at $3.00 each with attached warrants. It plans to put the cash toward working capital and other general purposes.
- IceCure said its U.S. ProSense install base for breast cancer cryoablation jumped 70% since the FDA gave marketing authorization, according to a separate update. Nasdaq is shut Friday for Juneteenth.
IceCure Medical shares looked volatile ahead of Thursday’s open, after the Israeli medical-device maker issued a U.S. commercial update alongside fresh financing news. The Nasdaq stock jumped 200.47% on Wednesday to close at $6.40. Pre-market, shares were at $7.27 at 6:59 a.m. EDT, according to Webull.
The move is in focus as investors look to price in early ProSense uptake in the U.S. after FDA marketing clearance, while factoring in the new share supply. Cryoablation, which freezes and destroys tissue, can be a less invasive option compared to surgery in some cases.
IceCure said Wednesday it will sell 1,833,334 ordinary shares or equivalents with Series D and Series E warrants to a single institutional investor focused on healthcare. Each share and attached warrants go for a combined $3.00, the company said. The private placement is targeted at specific investors, not the public.
The company said gross proceeds should come in around $5.5 million before fees, with closing set for on or about June 18, pending usual conditions. Proceeds are targeted for working capital and general purposes. Warrants attached to the deal have a $3.00 exercise price; Series D warrants run five years, Series E one year.
IceCure said Wednesday its active U.S. commercial install base for ProSense in breast cancer cryoablation climbed 70% since it got FDA marketing authorization in October 2025. The company said procedures have now taken place in Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and other cities.
Chief Executive Eyal Shamir said the company was in the “early stages of a significant commercial opportunity” around U.S. breast cancer cryoablation. Shamir also said physician training, education, and patient access are top priorities. PR Newswire
IceCure said its ProSense device is cleared for local treatment of low-risk breast cancer in women 70 or older who get adjuvant endocrine therapy. The clearance also covers women not eligible for surgery. Adjuvant endocrine therapy, a hormone-blocking treatment, is used after a local procedure to lower the risk of the cancer coming back.
Commercial headwinds matter as much as regulation. Big med-tech firms already market ablation tools. Boston Scientific’s ICEfx system targets minimally invasive cryoablation, while Varian/Siemens Healthineers has CryoCare Touch. IceCure is going after the same ground. It’s pushing for breast-cancer use and pitching doctors on an office-based model.
But the financing could limit gains if investors stay worried about dilution instead of the new cash. IceCure also said it would cut the exercise price on some March 2026 warrants to $3.00, down from $16.50, if shareholders and Nasdaq sign off. More exercises would mean more shares hitting the market. Risks listed by the company include sales execution, the need for more funds, regulation, IP issues and instability in Israel and the Middle East.
Nasdaq opens at 9:30 a.m. EDT and closes at 4 p.m. Regular trading won’t happen Friday, June 19, because of Juneteenth. Pre-market runs from 4 a.m. to 9:30 a.m., with Nasdaq warning that extended hours trading may come with less liquidity and higher volatility.
